BioCentury
ARTICLE | Company News

Myrexis cancer, infectious news

September 12, 2011 7:00 AM UTC

Myrexis disclosed in its 4Q11 earnings ended June 30 that it is discontinuing development of Azixa verubulin, a small molecule microtubule destabilizing apoptosis-inducer in Phase IIb testing for glioblastoma multiforme (GBM). According to the company, completing the Phase IIb trial would require a "disproportionate investment of time and resources relative to its likelihood of technical and regulatory success." Myrexis has exclusive rights to Azixa, which has Orphan Drug designation in the U.S. for the indication, from EpiCept Corp. (NASDAQ:EPCT; SSE:EPCT, Tarrytown, N.Y.). EpiCept declined to comment. ...